Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06516289 as recruiting, last updated 2024-12-12. Enrolment is 130 planned participants, an estimate. Interventions: HRS-1167, Famitinib, Camrelizumab. Primary measures include Safety run-in: Incidence rate of dose-limiting toxicities (DLTs); Safety run-in: adverse events (AEs). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/